Alison Reid
-
- Prostate Cancer Treatment and Research 18
- Prostate Cancer Diagnosis and Treatment 7
- Cancer Research top 2%
- Cancer, Lipids, and Metabolism 6
-
- Hormonal and reproductive studies 4
- Oncology top 5%
-
- Radiopharmaceutical Chemistry and Applications 4
-
- Estrogen and related hormone effects 5
-
- Testicular diseases and treatments 4
-
- Multiple Myeloma Research and Treatments 3
Alison Reid
32 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 86
- Pulmonary and Respiratory Medicine 1.9k
- Cancer Research 754
- Endocrinology, Diabetes and Metabolism 750
- Oncology 591
- Radiology, Nuclear Medicine and Imaging 446
Countries citing papers authored by Alison Reid
This map shows the geographic impact of Alison Reid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Reid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Reid more than expected).
Fields of papers citing papers by Alison Reid
This network shows the impact of papers produced by Alison Reid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Reid. The network helps show where Alison Reid may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Alison Reid, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 2 | |
| 4 | 2022 | 5 | |
| 5 | 2021 | 2 | |
| 6 | 2014 | 2 | |
| 7 | 2012 | 84 | |
| 8 | 2011 | 7 | |
| 9 | 2010 | 69 | |
| 10 | 2009 | 33 | |
| 11 | Abiraterone acetate: the novel application of a CYP450c17 inhibitor to the treatment of both prostate and breast cancer | 2009 | 1 |
| 12 | 2009 | 29 | |
| 13 | 2009 | 30 | |
| 14 | 2009 | 147 | |
| 15 | Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Drivenbreakdown → | 2008 | 666 |
| 16 | 2008 | 63 | |
| 17 | Selective inhibition of CYP17 with abiraterone acetate is well tolerated and results in a high response rate in castration-resistant prostate cancer (CRPC) | 2007 | 1 |
| 18 | 2007 | 126 | |
| 19 | 2007 | 112 | |
| 20 | Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors. | 2005 | 1 |
About Alison Reid
Alison Reid is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology, having authored 34 papers that have together received 2.7k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (18 papers), Prostate Cancer Diagnosis and Treatment (7 papers), Cancer, Lipids, and Metabolism (6 papers), Estrogen and related hormone effects (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers), Testicular diseases and treatments (4 papers), Hormonal and reproductive studies (4 papers) and Multiple Myeloma Research and Treatments (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.9k citations), Cancer Research (754 citations) and Endocrinology, Diabetes and Metabolism (750 citations). Alison Reid has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Johann S. de Bono, Gerhardt Attard, David P. Dearnaley, Elizabeth Folkerd, Mitch Dowsett, Gloria Lee, Christopher Parker, David Olmos, Stan B. Kaye and Nikhil Babu Oommen.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.